AbbVie Announced That The U.S. FDA Has Approved EPKINLY As The First And Only T-cell Engaging Bispecific Antibody Administered Subcutaneously For The Treatment Of Adults With Relapsed Or Refractory Follicular Lymphoma
AbbVie Announced That The U.S. FDA Has Approved EPKINLY As The First And Only T-cell Engaging Bispecific Antibody Administered Subcutaneously For The Treatment Of Adults With Relapsed Or Refractory Follicular Lymphoma
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.